[Chinese Expert Consensus of Allogeneic Hematopoietic Stem Cell Transplantation for Pediatric Acute Lymphoblastic Leukemia (2022)]

Overview

Journal Zhonghua Xue Ye Xue Za Zhi

Specialty Hematology

Date 2023 Jan 28

PMID 36709192

Affiliations

Soon will be listed here.

Citing Articles

[Analysis on the clinical efficacy and adverse reactions of blinatumomab for the treatment of relapsed/refractory acute lymphoblastic leukemia].

Shi Y, Han Y, Wang Y, Mao D, Zhang J, Xi R Zhonghua Xue Ye Xue Za Zhi. 2023; 44(6):516-519.

PMID: 37550212 PMC: 10450561. DOI: 10.3760/cma.j.issn.0253-2727.2023.06.015.

References

Chen Y, Cheng Y, Suo P, Yan C, Wang Y, Chen Y . Donor-derived CD19-targeted T cell infusion induces minimal residual disease-negative remission in relapsed B-cell acute lymphoblastic leukaemia with no response to donor lymphocyte infusions after haploidentical haematopoietic stem cell.... Br J Haematol. 2017; 179(4):598-605. DOI: 10.1111/bjh.14923. View

Chen Y, Zhang X, Cheng Y, Chen H, Mo X, Yan C . Long-term follow-up of CD19 chimeric antigen receptor T-cell therapy for relapsed/refractory acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation. Cytotherapy. 2020; 22(12):755-761. DOI: 10.1016/j.jcyt.2020.08.002. View

Xue Y, Wang Y, Jia Y, Zuo Y, Wu J, Lu A . The role of minimal residual disease in specific subtypes of pediatric acute lymphoblastic leukemia. Int J Hematol. 2021; 113(4):547-555. DOI: 10.1007/s12185-020-03063-w. View

Yu S, Huang F, Wang Y, Xu Y, Yang T, Fan Z . Haploidentical transplantation might have superior graft-versus-leukemia effect than HLA-matched sibling transplantation for high-risk acute myeloid leukemia in first complete remission: a prospective multicentre cohort study. Leukemia. 2019; 34(5):1433-1443. DOI: 10.1038/s41375-019-0686-3. View

Burke M, Kostadinov R, Sposto R, Gore L, Kelley S, Rabik C . Decitabine and Vorinostat with Chemotherapy in Relapsed Pediatric Acute Lymphoblastic Leukemia: A TACL Pilot Study. Clin Cancer Res. 2020; 26(10):2297-2307. PMC: 7477726. DOI: 10.1158/1078-0432.CCR-19-1251. View

Nijstad A, Barnett S, Lalmohamed A, Berenos I, Parke E, Carruthers V . Clinical pharmacology of cytotoxic drugs in neonates and infants: Providing evidence-based dosing guidance. Eur J Cancer. 2021; 164:137-154. PMC: 8914347. DOI: 10.1016/j.ejca.2021.11.001. View

Wang Y, Chang Y, Xu L, Liu K, Liu D, Zhang X . Who is the best donor for a related HLA haplotype-mismatched transplant?. Blood. 2014; 124(6):843-50. DOI: 10.1182/blood-2014-03-563130. View

Locatelli F, Whitlock J, Peters C, Chen-Santel C, Chia V, Dennis R . Blinatumomab versus historical standard therapy in pediatric patients with relapsed/refractory Ph-negative B-cell precursor acute lymphoblastic leukemia. Leukemia. 2020; 34(9):2473-2478. PMC: 7449874. DOI: 10.1038/s41375-020-0770-8. View

Tsaur G, Popov A, Riger T, Kustanovich A, Solodovnikov A, Shorikov E . Prognostic value of minimal residual disease measured by fusion-gene transcript in infants with KMT2A-rearranged acute lymphoblastic leukaemia treated according to the MLL-Baby protocol. Br J Haematol. 2021; 193(6):1151-1156. DOI: 10.1111/bjh.17304. View

10.

Hayashi H, Volt F, Sanz J, Petersen E, Dhedin N, Hough R . Myeloablative Unrelated Cord Blood Transplantation in Adolescents and Young Adults with Acute Leukemia. Biol Blood Marrow Transplant. 2019; 25(12):2438-2446. DOI: 10.1016/j.bbmt.2019.07.031. View

11.

Vora A, Goulden N, Mitchell C, Hancock J, Hough R, Rowntree C . Augmented post-remission therapy for a minimal residual disease-defined high-risk subgroup of children and young people with clinical standard-risk and intermediate-risk acute lymphoblastic leukaemia (UKALL 2003): a randomised controlled trial. Lancet Oncol. 2014; 15(8):809-18. DOI: 10.1016/S1470-2045(14)70243-8. View

12.

Zhang X, Chen J, Han M, Huang H, Jiang E, Jiang M . The consensus from The Chinese Society of Hematology on indications, conditioning regimens and donor selection for allogeneic hematopoietic stem cell transplantation: 2021 update. J Hematol Oncol. 2021; 14(1):145. PMC: 8441240. DOI: 10.1186/s13045-021-01159-2. View

13.

Maloney K, Devidas M, Wang C, Mattano L, Friedmann A, Buckley P . Outcome in Children With Standard-Risk B-Cell Acute Lymphoblastic Leukemia: Results of Children's Oncology Group Trial AALL0331. J Clin Oncol. 2019; 38(6):602-612. PMC: 7030893. DOI: 10.1200/JCO.19.01086. View

14.

Lovisa F, Zecca M, Rossi B, Campeggio M, Magrin E, Giarin E . Pre- and post-transplant minimal residual disease predicts relapse occurrence in children with acute lymphoblastic leukaemia. Br J Haematol. 2018; 180(5):680-693. DOI: 10.1111/bjh.15086. View

15.

Hu G, Cheng Y, Zuo Y, Chang Y, Suo P, Wu J . Chimeric Antigens Receptor T Cell Therapy Improve the Prognosis of Pediatric Acute Lymphoblastic Leukemia With Persistent/Recurrent Minimal Residual Disease in First Complete Remission. Front Immunol. 2022; 12:731435. PMC: 8777073. DOI: 10.3389/fimmu.2021.731435. View

16.

Hijiya N, Thomson B, Isakoff M, Silverman L, Steinherz P, Borowitz M . Phase 2 trial of clofarabine in combination with etoposide and cyclophosphamide in pediatric patients with refractory or relapsed acute lymphoblastic leukemia. Blood. 2011; 118(23):6043-9. PMC: 3731655. DOI: 10.1182/blood-2011-08-374710. View

17.

Horton T, Whitlock J, Lu X, OBrien M, Borowitz M, Devidas M . Bortezomib reinduction chemotherapy in high-risk ALL in first relapse: a report from the Children's Oncology Group. Br J Haematol. 2019; 186(2):274-285. PMC: 6606340. DOI: 10.1111/bjh.15919. View

18.

Bai L, Cheng Y, Lu A, Suo P, Wang Y, Zuo Y . Prognosis of haploidentical hematopoietic stem cell transplantation in non-infant children with t(v;11q23)/MLL-rearranged B-cell acute lymphoblastic leukemia. Leuk Res. 2020; 91:106333. DOI: 10.1016/j.leukres.2020.106333. View

19.

Yan C, Wang J, Liu D, Xu L, Chen H, Liu K . Chemotherapy followed by modified donor lymphocyte infusion as a treatment for relapsed acute leukemia after haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion: superior outcomes compared with chemotherapy alone.... Eur J Haematol. 2013; 91(4):304-14. DOI: 10.1111/ejh.12168. View

20.

van Dongen J, van der Velden V, Bruggemann M, Orfao A . Minimal residual disease diagnostics in acute lymphoblastic leukemia: need for sensitive, fast, and standardized technologies. Blood. 2015; 125(26):3996-4009. PMC: 4490298. DOI: 10.1182/blood-2015-03-580027. View